<DOC>
	<DOCNO>NCT00462345</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety MabThera combination methotrexate patient rheumatoid arthritis inadequate response one anti-TNF therapy . Patients receive MabThera 1000mg i.v . day 1 15 , methotrexate ( 10-25mg/week p.o . parenteral ) , together methylprednisolone 100mg i.v . prior infusion MabThera . After week 24 , eligible patient may receive re-treatment . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Combination With Methotrexate Patients With Rheumatoid Arthritis Who Have Had Inadequate Response Anti-TNF Therapies .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>adult patient , 1880 year age ; rheumatoid arthritis &gt; =6 month ; receive outpatient treatment ; inadequate response least one antiTNF therapy ; stable methotrexate &gt; =12 week . rheumatic autoimmune disease inflammatory joint disease ; previous treatment MabThera ; concurrent treatment DMARD ( apart methotrexate ) , antiTNF alpha therapy , biologic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>